Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
181
Frequently Asked Questions
What is Market Cap of Akebia Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Akebia Therapeutics Inc. market cap is $782.18M.
What is the 52-week high for Akebia Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Akebia Therapeutics Inc. 52 week high is $4.08 as of September 15, 2025.
What is the 52-week low for Akebia Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Akebia Therapeutics Inc. 52 week low is $1.24 as of September 15, 2025.
What is Akebia Therapeutics Inc. stock price today?
Akebia Therapeutics Inc. stock price today is $2.92.
What was Akebia Therapeutics Inc. stock price yesterday?
Akebia Therapeutics Inc. stock price yesterday was $2.95.
What is the PE ratio of Akebia Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Akebia Therapeutics Inc.’s P/E ratio is -17.02.
What is the Price-to-Book ratio of Akebia Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Akebia Therapeutics Inc. P/B ratio is 26.5527.
What is the 50-day moving average of Akebia Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Akebia Therapeutics Inc. 50-day moving average is $3.44.
How many employess does Akebia Therapeutics Inc. has?